Active Biotech to Present at Jefferies 2014 Healthcare Conference
June 03 2014 - 2:31AM
Lund, Sweden, June 3,
2014 - Active Biotech (NASDAQ OMX NORDIC: ACTI) is
scheduled to present at Jefferies 2014 Healthcare Conference held
June 2-5, 2014 in New York, US. During the presentation, an update
regarding Active Biotech's development programs will be
provided.
The presentation will include the laquinimod project, a novel oral
immunomodulatory drug primarily for the treatment of multiple
sclerosis, licensed to Teva Pharmaceutical, the Phase III prostate
cancer project tasquinimod in co-development with Ipsen, as well as
ANYARA, Active Biotech's novel concept for tumor therapy of
primarily renal cell cancer. Also, the project with paquinimod
(57-57) and the pre-clinical ISI project will be
presented.
The audio and slide presentation will be webcasted live and can be
accessed via the Active Biotech web site. To access the live and
replay presentations please go to -
www.activebiotech.com.
The presentation will take place on June 3, at 4:30 p.m. EDT /
10:30 p.m. CEST.
For further information, please contact:
Hans Kolam, CFO
Phone: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com
About
Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a
biotechnology company with focus on autoimmune/inflammatory
diseases and cancer. In pivotal phase is laquinimod, an orally
administered small molecule with unique immunomodulatory properties
for the treatment of multiple sclerosis. Also tasquinimod for the
treatment of prostate cancer, with an unique mode of action, is in
pivotal phase. In addition, laquinimod has concluded Phase II
development for Crohn's and Lupus. The company has two additional
projects in clinical development, ANYARA primarily for the
treatment of renal cell cancer and the orally administered compound
paquinimod (57-57) for systemic sclerosis. Please visit
www.activebiotech.com for more information.
Active Biotech AB (Corp. Reg. No.
556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 46 19 20 00
Fax: +46 46 19 11 00
Active Biotech is obligated to publish the
information contained in this press release in accordance with the
Swedish Securities Market Act. This information was provided to the
media for publication 08:30 a.m. CET on June 3, 2014.
Active Biotech to Present at
Jefferies 2014 Healthcare Conference
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Active Biotech via Globenewswire
HUG#1790029
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024